Key Takeaways
- • Apollo and KKR have completed a €3 billion investment in Bayer's long-acting reversible contraceptives business, with KKR participating as a significant minority investor alongside Apollo-managed funds.
- • Bayer retains majority ownership and full operational control of the business despite the equity infusion, positioning the deal as a structured capital partnership rather than a divestiture.
- • The transaction was originally announced in July 2026 and has now reached financial close, representing a significant midmarket healthcare asset deal in the contraceptives sector.
- • Aurelius has separately agreed to a $323 million carve-out of a Hain unit, indicating concurrent activity in the alternative investment marketplace around structured equity partnerships and business separations.
Summary
Apollo and KKR have finalized a €3 billion investment in Bayer's long-acting reversible contraceptives (LARC) business, marking a significant healthcare sector transaction for both alternative asset managers. The structure reflects a modern approach to capital partnership: rather than Bayer divesting the business entirely, Apollo-managed funds and KKR have invested equity into a newly created entity holding the contraceptives operation. This arrangement allows Bayer to monetize growth capital and unlock valuation from a specialized business segment while maintaining operational governance and majority ownership—a hybrid model increasingly common in large pharma portfolio optimization.
The deal, originally announced in July 2026, has now moved from signed stage to completion. KKR's role as a "significant minority participant" alongside Apollo suggests a co-investment structure, likely reflecting the deal's substantial size and the complementary capabilities both firms bring to healthcare infrastructure investments. The €3 billion enterprise value underscores institutional investor appetite for specialized pharmaceutical assets with recurring revenue characteristics, particularly in the contraceptives space where long-acting reversible methods represent a growing segment of global reproductive health spending.
Concurrent with this transaction, Aurelius has agreed to a $323 million carve-out of a Hain unit, demonstrating sustained dealmaking momentum in the alternative investment space around structured equity partnerships and business separations. These transactions reflect broader trends: large diversified corporations monetizing specialized business units through minority equity partnerships with sophisticated alternative investors, rather than traditional full-sale divestiture processes.
The deal, originally announced in July 2026, has now moved from signed stage to completion. KKR's role as a "significant minority participant" alongside Apollo suggests a co-investment structure, likely reflecting the deal's substantial size and the complementary capabilities both firms bring to healthcare infrastructure investments. The €3 billion enterprise value underscores institutional investor appetite for specialized pharmaceutical assets with recurring revenue characteristics, particularly in the contraceptives space where long-acting reversible methods represent a growing segment of global reproductive health spending.
Concurrent with this transaction, Aurelius has agreed to a $323 million carve-out of a Hain unit, demonstrating sustained dealmaking momentum in the alternative investment space around structured equity partnerships and business separations. These transactions reflect broader trends: large diversified corporations monetizing specialized business units through minority equity partnerships with sophisticated alternative investors, rather than traditional full-sale divestiture processes.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.